Ebola in Congo, 70,000 doses of Ervebo allocated: WHO warns that the effect on the Bundibugyo strain is not known
Twenty thousand doses go to a phase 3 clinical trial, fifty thousand to healthcare workers. The campaign uses ring vaccination. Africa CDC believes transmission has not yet peaked.
The Health section of the morning edition covered excess deaths from heatwaves in Europe. This afternoon it returns to the Congolese epidemic, starting from an action: the allocation of doses.
What was decided
On August 20, 2026, the World Health Organization announced the allocation of 70,000 doses of the Ervebo vaccine to the Democratic Republic of the Congo, drawing from the global stockpile. The announcement is joint with Africa CDC and is published on the WHO website.
The breakdown is the most significant part and the least reported: 20,000 doses are earmarked for a phase 3 clinical trial on the vaccine’s effect against the Bundibugyo virus, 50,000 for healthcare and frontline workers.
WHO Director-General Tedros Adhanom Ghebreyesus called the operation “an important example of global solidarity in action” (transl. from English).
The Congolese Minister of Health announced that 16,250 doses arrived at N’djili international airport in Kinshasa on August 21, as reported by the Associated Press and cited by the Washington Times. Administration is being carried out using the ring vaccination strategy, targeting contacts of confirmed cases and healthcare workers, according to the WHO Regional Office for Africa.
The limit that WHO itself declares
On this point, this newspaper’s editorial standards and the organization’s statement coincide: it is not known whether Ervebo protects humans against the Bundibugyo virus. This is stated by WHO, and it is the reason why twenty thousand doses are allocated to a study rather than to a campaign.
A phase 3 study serves precisely to establish, on a large population, what has not yet been established. At the moment, the sources cited in this piece do not make public the protocol, the precise size of the arms, the enrollment criteria, or the timeline for reading results. Until that data exists, the allocation is a logistical and research decision: it is not proof of efficacy, and this newspaper does not present it as such.
The epidemic’s numbers
| Indicator (WHO data as of August 1, 2026) | Value |
|---|---|
| Cases | 3,748 |
| Deaths | 1,657 |
| Recoveries | 708 |
These are figures reported by WHO and cited by UN News dated August 1: a count updated as of that date, not the most recent available overall, and should be read as such. Data from different bodies have different cutoff dates and are not directly comparable.
According to Africa CDC, transmission has not yet peaked and could reach triple the known rate: this is a projection by the continental agency, not a measurement.
Why containment is not working
The cited sources point to three concrete obstacles, all external to medicine: the ongoing armed conflict, attacks on healthcare personnel and facilities, and population displacement.
These are the three factors that break down ring vaccination. The strategy requires identifying the contacts of every confirmed case and reaching them within a useful timeframe: if the population is moving and healthcare workers are being attacked, the chain of contacts is lost. Seventy thousand allocated doses do not equal seventy thousand people reached.
Two follow-up checks are documentable: the arrival and distribution of the remaining doses beyond the 16,250 already landed in Kinshasa, and the publication of the phase 3 study protocol with its evaluation criteria.
← Archive · Front page · Past editorials · Report an error · Original article (in Italian)